Therapeutic Targeting of DNA Damage Response Pathways in TP53- and ATM-Mutated Tumors

This publication has 52 references indexed in Scilit:

• WEE1 inhibition in cancer therapy: Mechanisms, synergies, preclinical insights, and clinical trials
  Critical Reviews in Oncology/Hematology, 2025
• The Development of ATM Inhibitors in Cancer Therapy
  Targeted Oncology, 2025
• Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status
  Breast Cancer, 2024
• Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors
  JAMA Oncology, 2022
• Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced/metastatic melanoma who have failed prior anti-PD-1 therapy
  Annals of Oncology, 2022
• A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515)
  Pediatric Blood & Cancer, 2021
• A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer
  Investigational New Drugs, 2019
• ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response
  Molecular Cell, 2017
• Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors
  Cancer Chemotherapy and Pharmacology, 2014
• The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
  Molecular Oncology, 2011